RANIBIZUMAB-EQRN: 97 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
97
Total FAERS Reports
6 (6.2%)
Deaths Reported
0
Hospitalizations
97
As Primary/Secondary Suspect
Prescription
Status
FDA Application: 761165 ·
First Report: 20230426 · Latest Report: 20250107
What Are the Most Common RANIBIZUMAB-EQRN Side Effects?
#1 Most Reported
Product administration error
13 reports (13.4%)
#2 Most Reported
Product contamination
9 reports (9.3%)
#3 Most Reported
Product storage error
8 reports (8.2%)
All RANIBIZUMAB-EQRN Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Product administration error | 13 | 13.4% | 0 | 0 |
| Product contamination | 9 | 9.3% | 0 | 0 |
| Product storage error | 8 | 8.3% | 0 | 0 |
| Circumstance or information capable of leading to medication error | 7 | 7.2% | 0 | 0 |
| Visual impairment | 7 | 7.2% | 0 | 0 |
| Death | 6 | 6.2% | 6 | 0 |
| Drug ineffective | 6 | 6.2% | 0 | 0 |
| Product use issue | 6 | 6.2% | 0 | 0 |
| Vision blurred | 5 | 5.2% | 0 | 0 |
Who Reports RANIBIZUMAB-EQRN Side Effects? Age & Gender Data
Gender: 75.0% female, 25.0% male. Average age: 85.6 years. Most reports from: US. View detailed demographics →
Is RANIBIZUMAB-EQRN Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2023 | 14 | 3 | 0 |
| 2024 | 44 | 2 | 0 |
| 2025 | 4 | 0 | 0 |
What Is RANIBIZUMAB-EQRN Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 72 |
| Neovascular age-related macular degeneration | 11 |
| Macular degeneration | 6 |
Official FDA Label for RANIBIZUMAB-EQRN
Official prescribing information from the FDA-approved drug label.